<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRPO</journal-id><journal-title-group><journal-title>Asian Case Reports in Oncology</journal-title></journal-title-group><issn pub-type="epub">2169-8821</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRPO.2020.94005</article-id><article-id pub-id-type="publisher-id">ACRPO-38322</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRPO20200400000_36807121.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  参麦注射液防治恶性血液病化疗中胃肠道反应疗效观察
   The Observation of the Efficacy of Shenmai Injection in Preventing and Treating Gastrointestinal Reactions during Chemotherapy of Hematological Malignancies
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>翠娥</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>江苏省大丰人民医院，江苏 大丰</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>10</month><year>2020</year></pub-date><volume>09</volume><issue>04</issue><fpage>22</fpage><lpage>25</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：观察参麦注射液防治恶性血液病化疗中胃肠道反应的疗效。方法：2016年1月~2017年12月，我院选择60例恶性血液病化疗病例，随机分成实验组及对照组2组，实验组化疗过程中应用参麦注射液，对照组不加用参麦注射液，观察化疗过程中胃肠道副反应。结论：应用参麦注射液(正大青春宝药业有限公司生产)静滴防治胃肠道副反应收到明显效果。 Aim: To observe the efficacy of Shenmai injection in preventing and treating gastrointestinal reactions during chemotherapy of hematological malignancies. Methods: From January 2016 to December 2017, our hospital selected 60 cases of chemotherapy for hematological malignancies and randomly divided them into two groups: an experimental group and a control group. The experimental group was treated with Shenmai injection during chemotherapy, and the control group did not use Shenmai injection. Gastrointestinal adverse effects are observed during chemotherapy. Conclusion: The application of Shenmai injection (produced by Zhengda Qingchunbao Pharmaceutical Co., Ltd.) intravenously in the prevention and treatment of gastrointestinal adverse effects has achieved significant results. 
  
 
</p></abstract><kwd-group><kwd>参麦，恶性血液病，化疗，胃肠道反应,  Shenmai</kwd><kwd> Hematologic Malignancies</kwd><kwd> Chemotherapy</kwd><kwd> Gastrointestinal Reactions</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察参麦注射液防治恶性血液病化疗中胃肠道反应的疗效。方法：2016年1月~2017年12月，我院选择60例恶性血液病化疗病例，随机分成实验组及对照组2组，实验组化疗过程中应用参麦注射液，对照组不加用参麦注射液，观察化疗过程中胃肠道副反应。结论：应用参麦注射液(正大青春宝药业有限公司生产)静滴防治胃肠道副反应收到明显效果。</p></sec><sec id="s2"><title>关键词</title><p>参麦，恶性血液病，化疗，胃肠道反应</p></sec><sec id="s3"><title>The Observation of the Efficacy of Shenmai Injection in Preventing and Treating Gastrointestinal Reactions during Chemotherapy of Hematological Malignancies<sup> </sup></title><p>Cui’e Sun</p><p>Dafeng People’s Hospital of Jiangsu Province, Dafeng Jiangsu</p><p><img src="//html.hanspub.org/file/2-2530105x4_hanspub.png" /></p><p>Received: Oct. 7<sup>th</sup>, 2020; accepted: Oct. 21<sup>st</sup>, 2020; published: Oct. 28<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/2-2530105x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Aim: To observe the efficacy of Shenmai injection in preventing and treating gastrointestinal reactions during chemotherapy of hematological malignancies. Methods: From January 2016 to December 2017, our hospital selected 60 cases of chemotherapy for hematological malignancies and randomly divided them into two groups: an experimental group and a control group. The experimental group was treated with Shenmai injection during chemotherapy, and the control group did not use Shenmai injection. Gastrointestinal adverse effects are observed during chemotherapy. Conclusion: The application of Shenmai injection (produced by Zhengda Qingchunbao Pharmaceutical Co., Ltd.) intravenously in the prevention and treatment of gastrointestinal adverse effects has achieved significant results.</p><p>Keywords:Shenmai, Hematologic Malignancies, Chemotherapy, Gastrointestinal Reactions</p><disp-formula id="hanspub.38322-formula66"><graphic xlink:href="//html.hanspub.org/file/2-2530105x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2530105x7_hanspub.png" /> <img src="//html.hanspub.org/file/2-2530105x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>血液系统恶性肿瘤和实体肿瘤不同，不适合手术和放疗，大多数都需要化疗，化疗耐受性是影响疗效的主要因素之一。我们需要通过药物来减轻化疗不良反应，增加机体耐受性，为既定方案取得良好疗效提供保障和机会。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>所选病例60人，年龄在45周岁~65周岁之间，均为恶性血液病住院患者，诊断均符合《血液病诊断及疗效标准》(张之南主编，第2版，北京科学出版社)。其中，男35例，女25例，急性髓细胞白血病13例，急性淋巴细胞白血病10例；恶性淋巴瘤15例，多发性骨髓瘤15例，慢粒急淋变2例，慢淋进展3例，原发性巨球蛋白血症2例，体能PS评分均在70分以上，无胃肠道器质性病变，膈肌病变，高颅压或引起顽固性呕吐相关病因，化疗前一周无恶心呕吐症状，无止吐药物应用史。均对参麦无过敏反应，60例病人中，初诊诱导化疗15例，早期巩固化疗25例，晚期强化治疗20例。</p></sec><sec id="s6_2"><title>2.2. 化疗方案与止吐药物</title><p>急非淋IA方案，伊达比星8~12 mg/m<sup>2</sup>/d，d 1~3，阿糖胞苷0.1 /m<sup>2</sup>/d，d 1~7。急淋VDP方案：长春地辛4 mg qw d 1.8.15.22，柔红霉素45 mg/m<sup>2</sup>/d，d 1~3，强的松1~2 mg/kg/d d 1~14，0.5~1 mg/kg/d，d 15~28；恶性淋巴瘤，弥漫大B细胞淋巴瘤CHOP方案：环磷酰胺0.5/m<sup>2</sup> d 1，表柔比星60~90 mg/m<sup>2</sup> d 1，长春地辛4 mg d 1，强的松1 mg/kg/d，d 1~5，T细胞淋巴瘤CHOP方案，铜钱，或GDP方案，吉西他滨1.0/m<sup>2</sup>/d d 1，8，顺铂30 mg d 1~4，地塞米松40 mg d 1~4，多发性骨髓瘤VAD方案，长春地辛1 mg/d，d 1~4，多柔比星10 mg/d，d 1~4加或不加硼替佐米1.3 mg/m<sup>2</sup>，d 1，4，8，11。慢粒急淋变同急淋，急髓变同急非淋，慢性淋巴细胞白血病进展及原发性巨球蛋白血症化疗方案：FC方案，福达拉滨25 mg/m<sup>2</sup>，d 1~3，环磷酰胺250 mg/m<sup>2</sup>，d 1~3，化疗药物剂量按个体每平米体表面积用药的中等剂量给药，止吐药物剂量按中等剂量给药。60例病人随机分成参麦组及对照组，参麦组化疗同时给予参麦40~60 ml/d于5%葡萄糖250 ml中，共7~10天，VDP方案化疗是与化疗同步。</p></sec><sec id="s6_3"><title>2.3. 胃肠道副反应分级及疗效评价 [<xref ref-type="bibr" rid="hanspub.38322-ref1">1</xref>]</title><p>按WHO标准观察恶心呕吐表现0级，无症状，I级：恶心；II级：偶尔呕吐；III级：频繁呕吐；IV级，频繁呕吐，难以控制。止吐效果评价：CR：完全缓解，无呕吐，PR：部分缓解，呕吐1~2次/天，轻度缓解MR：3~5次/天；NR：无效，呕吐大于6次/天。以CR + PR计算有效率。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用X<sup>2</sup>检验，P &lt; 0.05，有统计学意义。</p></sec></sec><sec id="s7"><title>3. 胃肠道副反应分级及疗效评价观察结果，见表1</title><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The grade of gastrointestinal reactions and the evaluation of therapeutic efficac</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >实验组30例</th><th align="center" valign="middle"  colspan="2"  >对照组30例</th></tr></thead><tr><td align="center" valign="middle"  rowspan="5"  >胃肠道副反应分级</td><td align="center" valign="middle" >0级</td><td align="center" valign="middle" >12例</td><td align="center" valign="middle" >0级</td><td align="center" valign="middle" >8例</td></tr><tr><td align="center" valign="middle" >I级</td><td align="center" valign="middle" >11例</td><td align="center" valign="middle" >I级</td><td align="center" valign="middle" >7例</td></tr><tr><td align="center" valign="middle" >II级</td><td align="center" valign="middle" >6例</td><td align="center" valign="middle" >II级</td><td align="center" valign="middle" >10例</td></tr><tr><td align="center" valign="middle" >III级</td><td align="center" valign="middle" >1例</td><td align="center" valign="middle" >III级</td><td align="center" valign="middle" >4例</td></tr><tr><td align="center" valign="middle" >IV级</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >IV级</td><td align="center" valign="middle" >1例</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >止吐疗效评价</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >12例</td><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >8例</td></tr><tr><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >17例</td><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >14例</td></tr><tr><td align="center" valign="middle" >MR</td><td align="center" valign="middle" >1例</td><td align="center" valign="middle" >MR</td><td align="center" valign="middle" >6例</td></tr><tr><td align="center" valign="middle" >NR</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >NR</td><td align="center" valign="middle" >2例</td></tr><tr><td align="center" valign="middle" >有效率</td><td align="center" valign="middle"  colspan="2"  >95.00%</td><td align="center" valign="middle"  colspan="2"  >73.33%</td></tr></tbody></table></table-wrap><p>表1. 胃肠道副反应分级及疗效评价</p><p>通过上表可以得出结论，实验组止吐有效率明显高于对照组，P &lt; 0.05，有统计学意义。</p></sec><sec id="s8"><title>4. 讨论</title><p>化疗是治疗血液系统恶性肿瘤的主要手段之一，大多数化疗药物均可引起程度不等，不同类型的胃肠道反应，主要表现为食欲不振，恶心呕吐，腹泻，便秘 [<xref ref-type="bibr" rid="hanspub.38322-ref2">2</xref>]，往往严重影响既定方案的顺利完成，化疗药物在抑制和杀死肿瘤细胞的同时对机体正常细胞也有一定的毒副作用，特别是对增生活跃的组织细胞如血细胞，胃肠道细胞等 [<xref ref-type="bibr" rid="hanspub.38322-ref3">3</xref>]，在化疗时就会产生相应的副反应，所有化疗药物均可引起消化道反应，比如口腔溃疡，食欲不振，恶心呕吐，腹痛腹泻。参麦注射液由纯中药人参和麦冬提炼而成，药理研究证明人参具有“适应源”样作用，即能增强机体对有害刺激的防御能力。具有明显的抗应激作用，提高免疫功能 [<xref ref-type="bibr" rid="hanspub.38322-ref4">4</xref>]。麦冬具有养阴润燥，清热除烦，与人参配伍，能增强人参的作用，以其甘寒之性制约人参之温性，使其趋于平衡。参麦通过静脉给药，不仅可以迅速进入体内，尽快发挥其药效，同时也避免了化疗病人口服给药容易引起呕吐的弊病，参麦对白细胞减少疗效亦为显著 [<xref ref-type="bibr" rid="hanspub.38322-ref5">5</xref>]，总之参麦注射液配合化疗有明显的增效减毒作用，减轻化疗所引起的恶心呕吐，食欲不振症状，与枢丹等止吐药合用有增效协同作用，是较好的止吐辅助良药，值得临床推广应用。</p></sec><sec id="s9"><title>文章引用</title><p>孙翠娥. 参麦注射液防治恶性血液病化疗中胃肠道反应疗效观察 The Observation of the Efficacy of Shenmai Injection in Preventing and Treating Gastrointestinal Reactions during Chemotherapy of Hematological Malignancies[J]. 亚洲肿瘤科病例研究, 2020, 09(04): 22-25. https://doi.org/10.12677/ACRPO.2020.94005</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38322-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">姜文奇, 孙晓非, 张力, 等. 实用肿瘤内科处方用药手册[M]. 第2版. 广州: 广东科技出版社, 2009.</mixed-citation></ref><ref id="hanspub.38322-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">刘志艳, 王学谦, 林洪生, 等. 林洪生应用中医药防治化疗后毒副反应经验浅析[J]. 世界中西医结合杂志, 2015, 10(3): 314-316, 319.</mixed-citation></ref><ref id="hanspub.38322-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">岳颖. 恶性肿瘤患者化疗后诱发口腔溃疡的研究进展[J]. 护士进修杂志, 2008, 23(2): 144-146.</mixed-citation></ref><ref id="hanspub.38322-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">高学敏. 中药学[M]. 北京: 中国中医药出版社, 2002: 498-551.</mixed-citation></ref><ref id="hanspub.38322-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">王建英, 钟雪梅. 参麦注射液对急性白血病化疗患者骨髓造血功能保护作用的研究[J]. 中国中西医结合杂志, 2005, 25(3): 266-267.</mixed-citation></ref></ref-list></back></article>